SIGY (Sigyn Therapeutics) Cyclically Adjusted FCF per Share: $-36.26 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sigyn Therapeutics Cyclically Adjusted FCF per Share?

Sigyn Therapeutics SIGY -6.00% Cyclically Adjusted FCF per Share is $-36.26 as of Sep. 2025. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sigyn Therapeutics's adjusted free cash flow per share for the three months ended in Sep. 2025 was $-0.124. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-36.26 for the trailing ten years ended in Sep. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-16), Sigyn Therapeutics's current stock price is $0.0235. Sigyn Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2025 was $-36.26. Sigyn Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Sigyn Therapeutics  (OTCPK:SIGY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sigyn Therapeutics Cyclically Adjusted FCF per Share Related Terms


Sigyn Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Sigyn Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigyn Therapeutics Cyclically Adjusted FCF per Share Chart

Sigyn Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -38.21

Sigyn Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.12 -38.21 -37.66 -36.97 -36.26

SIGY vs RGBP, ENDV, VRTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Sigyn Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sigyn Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Sigyn Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sigyn Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=-0.124/324.8000*324.8000
=-0.124

Current CPI (Sep. 2025) = 324.8000.

Sigyn Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 236.525 0.000
201603 -46.500 238.132 -63.424
201606 5.500 241.018 7.412
201609 -71.500 241.428 -96.191
201612 0.000 241.432 0.000
201703 -20.000 243.801 -26.645
201706 -14.143 244.955 -18.753
201709 -1.250 246.819 -1.645
201712 -25.556 246.524 -33.671
201803 -32.200 249.554 -41.909
201806 -0.700 251.989 -0.902
201809 2.727 252.439 3.509
201812 0.923 251.233 1.193
201903 -5.214 254.202 -6.662
201906 0.571 256.143 0.724
201909 -3.500 256.759 -4.427
201912 -2.143 256.974 -2.709
202003 -0.286 258.115 -0.360
202006 -26.385 257.797 -33.243
202009 -15.538 260.280 -19.390
202012 -0.319 260.474 -0.398
202103 -0.314 264.877 -0.385
202106 -0.447 271.696 -0.534
202109 -0.607 274.310 -0.719
202112 -0.605 278.802 -0.705
202203 -0.494 287.504 -0.558
202206 -0.424 296.311 -0.465
202209 -0.562 296.808 -0.615
202212 -0.480 296.797 -0.525
202303 -0.585 301.836 -0.630
202306 -0.304 305.109 -0.324
202309 -0.329 307.789 -0.347
202312 -0.102 306.746 -0.108
202403 -0.192 312.332 -0.200
202406 -0.148 314.175 -0.153
202409 -0.129 315.301 -0.133
202412 -0.182 315.605 -0.187
202503 -0.183 319.799 -0.186
202506 -0.095 322.561 -0.096
202509 -0.124 324.800 -0.124

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-36.26 mean?
Sigyn Therapeutics (SIGY) has a Cyclically Adjusted FCF per Share of $-36.26 as of Sep. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sigyn Therapeutics and its competitors.
Is Sigyn Therapeutics' Cyclically Adjusted FCF per Share too high?
Sigyn Therapeutics' current Cyclically Adjusted FCF per Share is $-36.26.
How does Sigyn Therapeutics' Cyclically Adjusted FCF per Share compare to RGBP and ENDV?
Sigyn Therapeutics' Cyclically Adjusted FCF per Share of $-36.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sigyn Therapeutics and its competitors. Sigyn Therapeutics's current Cyclically Adjusted FCF per Share is $-36.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current Cyclically Adjusted FCF per Share of $-36.26. The current Cyclically Adjusted FCF per Share is $-36.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current Cyclically Adjusted FCF per Share is $-36.26 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.